Clinical Trial Update: Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating 186 mcg of OPN-375 nasal spray twice daily in adolescents with chronic rhinosinusitis without nasal polyps, focusing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis Without Nasal Polyps

Drugs mentioned

• OPN-375 nasal spray (OPN-375)

Snippet

Sponsor: Optinose US Inc. | Conditions: Chronic Rhinosinusitis Without Nasal Polyps | Phase 3 | Status: RECRUITING